Den første undersøgelse omfattede 2 035 patienter, som ikke tidligere havde været behandlet, og den anden omfattede 627 patienter, der tidligere forgæves var forsøgt behandlet med irinotecan og et fluoropyrimidin (en gruppe kræftlægemidler, der omfatter 5 - FU).
Xeloda has also been compared with the combination of 5-FU and folinic acid, both in combination with oxaliplatin (another anticancer medicine), in two studies: the first involved 2,035 patients who had not been treated before, and the second involved 627 patients who had failed previous treatment with irinotecan and a fluoropyrimidine (a group of anticancer medicines that includes 5-FU).